Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$6.79+0.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · CPIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing ifetroban through multiple Phase 2 clinical programs targeting Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis prevention.
Stated as a priority in 3 of last 3 quarters. Cumberland has advanced ifetroban through multiple Phase 2 clinical programs targeting Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis prevention. The program has received FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations. The trajectory shows consistent focus and clinical progress aligned with management's stated development goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases.”
“The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.”
“Cumberland is developing ifetroban through a series of clinical programs designed to address unmet medical needs with significant market potential.”
Finalize the strategic transaction with Apotex, transferring FDA-approved brands and transitioning Cumberland to a development-stage biopharmaceutical company.
Stated as a priority in 3 of last 3 quarters. Cumberland completed the strategic transaction with Apotex, receiving $100 million in cash and transitioning its FDA-approved brands. The transaction was approved by shareholders with over 99% support. This milestone was achieved as planned, delivering on management's stated integration objective.
“Cumberland completed a transaction with Apotex Health to integrate their branded business for $100 million in cash at closing.”
“The transaction was unanimously approved by Cumberland's Board and shareholders with over 99% voting in favor.”
“Cumberland announced a Strategic Transaction with Apotex to integrate the branded U.S. commercial businesses.”
Distribute excess cash from the Apotex transaction through a special dividend and authorize a share repurchase program to return capital to shareholders.
Stated as a priority in 2 of last 3 quarters. Following the Apotex transaction, Cumberland declared a special dividend of $1.50 per share and authorized a $5 million share repurchase program. The dividend was paid on July 31, 2026. Management has delivered on capital return commitments with liquidity retained for development efforts.
“Cumberland's Board authorized and declared a special cash dividend of $1.50 per share payable July 31, 2026.”
“The Board authorized an open-market share repurchase program of up to $5 million over time.”
Sustain and build on prior revenue growth momentum aiming for double-digit growth in annual revenues.
Stated as a priority in 2 of last 3 quarters. Cumberland reported 23% revenue growth in first half of 2025 and targeted double-digit growth for 2026. However, reported revenues declined sharply in 2026-Q2 to $166K due to the divestiture of branded products, indicating the revenue growth priority is transitioning with the business model shift.
“Achieving the company’s target of double digit revenue growth.”
“Year-to-date revenues for the first six months totaled $22.6 million, a 23% increase over first half of 2024.”
Advance clinical development of ifetroban across multiple Phase 2 programs targeting Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis prevention.
Over the trailing year it converted 0.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.